Watson-Kissei’s Silodosin For BPH Could Have Oct. 14 User Fee Date
This article was originally published in PharmAsia News
Executive Summary
Generic specialist Watson Pharmaceuticals and Japan's Kissei Pharmaceutical said Feb. 13 that the U.S. FDA had accepted their filing of a new drug application for silodosin to treat signs and symptoms associated with benign prostatic hyperplasia
You may also be interested in...
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required.)